141 related articles for article (PubMed ID: 31255485)
1. Development of a novel inducer for EBV lytic therapy.
Tikhmyanova N; Paparoidamis N; Romero-Masters J; Feng X; Mohammed FS; Reddy PAN; Kenney SC; Lieberman PM; Salvino JM
Bioorg Med Chem Lett; 2019 Aug; 29(16):2259-2264. PubMed ID: 31255485
[TBL] [Abstract][Full Text] [Related]
2. Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus.
Tikhmyanova N; Schultz DC; Lee T; Salvino JM; Lieberman PM
ACS Chem Biol; 2014 Mar; 9(3):785-95. PubMed ID: 24028149
[TBL] [Abstract][Full Text] [Related]
3. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
4. Genipin as a novel chemical activator of EBV lytic cycle.
Son M; Lee M; Ryu E; Moon A; Jeong CS; Jung YW; Park GH; Sung GH; Cho H; Kang H
J Microbiol; 2015 Feb; 53(2):155-65. PubMed ID: 25626372
[TBL] [Abstract][Full Text] [Related]
5. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Hui KF; Chiang AK
Int J Cancer; 2010 May; 126(10):2479-89. PubMed ID: 19816947
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation.
Lee HG; Kim H; Kim EJ; Park PG; Dong SM; Choi TH; Kim H; Chong CR; Liu JO; Chen J; Ambinder RF; Hayward SD; Park JH; Lee JM
Oncotarget; 2015 Oct; 6(31):31018-29. PubMed ID: 26427042
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression.
Feng WH; Kenney SC
Cancer Res; 2006 Sep; 66(17):8762-9. PubMed ID: 16951192
[TBL] [Abstract][Full Text] [Related]
9. Sulfated small molecules targeting eBV in Burkitt lymphoma: from in silico screening to the evidence of in vitro effect on viral episomal DNA.
Lima RT; Seca H; Palmeira A; Fernandes MX; Castro F; Correia-da-Silva M; Nascimento MS; Sousa E; Pinto M; Vasconcelos MH
Chem Biol Drug Des; 2013 May; 81(5):631-44. PubMed ID: 23350710
[TBL] [Abstract][Full Text] [Related]
10. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
11. Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies.
Choi CK; Ho DN; Hui KF; Kao RY; Chiang AK
PLoS One; 2015; 10(12):e0145994. PubMed ID: 26717578
[TBL] [Abstract][Full Text] [Related]
12. Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells.
Rao SP; Rechsteiner MP; Berger C; Sigrist JA; Nadal D; Bernasconi M
Mol Cancer; 2007 Jan; 6():3. PubMed ID: 17214905
[TBL] [Abstract][Full Text] [Related]
13. Quercetin-induced apoptosis prevents EBV infection.
Lee M; Son M; Ryu E; Shin YS; Kim JG; Kang BW; Cho H; Kang H
Oncotarget; 2015 May; 6(14):12603-24. PubMed ID: 26059439
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.
Feng WH; Israel B; Raab-Traub N; Busson P; Kenney SC
Cancer Res; 2002 Mar; 62(6):1920-6. PubMed ID: 11912175
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine.
Anderson AG; Gaffy CB; Weseli JR; Gorres KL
Viruses; 2019 May; 11(5):. PubMed ID: 31108875
[TBL] [Abstract][Full Text] [Related]
16. Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer.
Zhao J; Jin H; Cheung KF; Tong JH; Zhang S; Go MY; Tian L; Kang W; Leung PP; Zeng Z; Li X; To KF; Sung JJ; Yu J
Cancer; 2012 Feb; 118(4):924-36. PubMed ID: 21717425
[TBL] [Abstract][Full Text] [Related]
17. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
18. Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation.
Thomé MP; Borde C; Larsen AK; Henriques JAP; Lenz G; Escargueil AE; Maréchal V
Antiviral Res; 2019 Dec; 172():104615. PubMed ID: 31580916
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression.
Zheng X; Wang J; Wei L; Peng Q; Gao Y; Fu Y; Lu Y; Qin Z; Zhang X; Lu J; Ou C; Li Z; Zhang X; Liu P; Xiong W; Li G; Yan Q; Ma J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209170
[TBL] [Abstract][Full Text] [Related]
20. The biological properties of different Epstein-Barr virus strains explain their association with various types of cancers.
Tsai MH; Lin X; Shumilov A; Bernhardt K; Feederle R; Poirey R; Kopp-Schneider A; Pereira B; Almeida R; Delecluse HJ
Oncotarget; 2017 Feb; 8(6):10238-10254. PubMed ID: 28052012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
